Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update - PubMed
5 hours ago
- #Gastroesophageal Cancer
- #ASCO Guidelines
- #Immunotherapy
- Updated ASCO guidelines for immunotherapy and targeted therapy in advanced gastroesophageal cancer.
- Target population: patients with unresectable locally advanced, advanced, or metastatic gastroesophageal cancer.
- Immunotherapy with doublet chemotherapy recommended for pMMR/MSS HER2-negative patients with PD-L1 ≥1.
- Zolbetuximab recommended for gastroesophageal adenocarcinoma with PD-L1 <1 and positive CLDN18.2 expression.
- Doublet chemotherapy alone recommended for patients without actionable biomarkers or ineligible for targeted therapy/immunotherapy.
- Trastuzumab and doublet chemotherapy recommended for pMMR/MSS HER2-positive patients; pembrolizumab added if PD-L1 ≥1.
- Immunotherapy alone or with doublet chemotherapy recommended for dMMR/MSI-high gastroesophageal cancer.
- Second-line options include ramucirumab with paclitaxel, trastuzumab deruxtecan for HER2-positive, and immunotherapy for PD-L1 ≥1 esophageal squamous cell carcinoma.